Coya Therapeutics’ QQ3 2024 results underscore the challenges typical of a late-stage development-stage biotech: the company remains without commercial revenue, operating losses continue, and cash burn drives near-term liquidity considerations. For the quarter ended September 30, 2024, COYA reported an operating and net loss of approximately $4.45 million and $4.02 million respectively, with R&D expenses of about $2.22 million and G&A of about $2.22 million. The company generated no reported revenue in QQ3 2024, contributing to a trailing four-quarter revenue run rate of roughly $9.6 million when including the prior periods in 2023; nonetheless, this is small relative to the ongoing burn and the company’s pipeline investments. COYA’s balance sheet shows a robust liquidity position, with cash and cash equivalents of $31.1 million and no debt, yielding a healthy current ratio (~15x). Net debt is effectively negative by a similar magnitude to cash, highlighting a strengthened liquidity cushion to fund ongoing R&D through anticipated pipeline catalysts. In terms of outlook, management commentary specific forward targets were not disclosed in the data provided; however, the company’s core value driver remains the advancement of its Treg-focused therapies (COYA101, COYA301/COYA302, and exosome programs COYA201/COYA206). The near-term investment thesis hinges on successful clinical progress, potential strategic collaborations, and the ability to extend runway through continued financing or partnering transactions. Investors should monitor upcoming clinical milestones, readouts from IND-enabling studies, and any partnership activity that could de-risk development and provide non-dilutive or less-dilutive funding.